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Summary
 
Effective long-term antiviral immunity requires specific cytotoxic T lymphocytes and CD4
 
1
 
 T
lymphocyte help. Failure of these helper responses can be a principle cause of viral persistence.
We sought evidence that variation in HIV-1 CD4
 
1
 
 T helper epitopes might contribute to this
phenomenon. To determine this, we assayed fresh peripheral blood mononuclear cells from 43
asymptomatic HIV-1
 
1
 
 patients for proliferative responses to HIV-1 antigens. 12 (28%) showed
a positive response, and we went on to map dominant epitopes in two individuals, to p24 Gag
restricted by human histocompatibility leukocyte antigen (HLA)-DR1 and to p17 Gag re-
stricted by HLA-DRB52c. Nine naturally occurring variants of the p24 Gag epitope were
found in the proviral DNA of the individual in whom this response was detected. All variants
bound to HLA-DR1, but three of these peptides failed to stimulate a CD4
 
1
 
 T lymphocyte line
which recognized the index sequence. Antigenic variation was also detected in the p17 Gag
epitope; a dominant viral variant present in the patient was well recognized by a specific CD4
 
1
 
T lymphocyte line, whereas several natural mutants were not. Importantly, variants detected at
both epitopes also failed to stimulate fresh uncultured cells while index peptide stimulated suc-
cessfully. These results demonstrate that variant antigens arise in HIV-1
 
1
 
 patients which fail to
stimulate the T cell antigen receptor of HLA class II–restricted lymphocytes, although the pep-
tide epitopes are capable of being presented on the cell surface. In HIV-1 infection, naturally
occurring HLA class II–restricted altered peptide ligands that fail to stimulate the circulating T
lymphocyte repertoire may curtail helper responses at sites where variant viruses predominate.
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L
 
oss and malfunction of CD4
 
1
 
 lymphocytes is one of
the hallmarks of HIV-1 infection (1). Before severe
CD4
 
1
 
 lymphocyte depletion occurs, defective proliferation
of these cells to recall antigens is common (2, 3). Few stud-
ies have detected specific proliferative responses to HIV-1–
derived antigens in HIV
 
1
 
 individuals. Recently, Rosen-
berg et al. (4) detected p24 Gag–specific helper responses in
two HIV-1
 
1
 
 individuals with long-term nonprogressive
disease. They also found that the use of potent highly active
antiretroviral therapy restored p24 Gag proliferative re-
sponses.
Antigenic variation in HIV-1 HLA class I–restricted
epitopes has been shown to cause loss of T cell recognition
(5–8). Some of these variant antigens failed to bind to the
HLA class I molecule (9, 10). Other epitope variants failed
to trigger the full T cell signaling cascade (11) despite par-
tial engagement of the TCR. Studies carried out on HLA
class II–restricted T cell responses in HIV-1 seronegative
individuals showed that CD4 responses were also influ-
enced by antigenic variation (12), but further work on Th
cells has been frustrated by the difficulty of detecting such
responses in HIV-1
 
1
 
 individuals at any stage of infection.
We detected responses in asymptomatic HIV-1
 
1
 
 patients
who had not received any antiretroviral therapy, many of
whom had long-term disease. We were also able to localize
a dominant CD4
 
1
 
 lymphocyte response to HIV-1 Gag
peptides in two individuals. Proviral DNA sequencing re-
vealed substantial sequence variation within both these
peptide epitopes. In general, epitope variation did not di-
minish binding to class II molecules, although several of the
variants detected failed to stimulate proliferation of both
fresh PBMCs and cultured T cell lines.
 
Preliminary data were reported at the March 1996 Keystone Symposium,
Immunopathogenesis of HIV Infection, Hilton Head, SC.
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Materials and Methods
 
Patient Details.
 
43 HIV-1
 
1
 
 patients were screened for CD4
 
1
 
lymphocyte proliferative responses. The duration of infection
varied from 10 to 
 
,
 
1 yr; all the patients were asymptomatic.
 
Peptides and Recombinant Antigens.
 
Peptides were obtained from
the Medical Research Council AIDS Directed Programme and
included 22 20-mers overlapping by 10 amino acids (aa)
 
1
 
 cover-
ing all of p24 Gag (aa 133–363 of HIV-1 SF2) and 13 15-mers
covering all of p17 Gag overlapping by 5 aa (aa 1–134 of HIV-
1SF2). Synthetic peptides representing the variant viral sequences
detected in the blood of the patients were manufactured by stan-
dard f-moc chemistry using an automated synthesizer (model
SMP2 350; Zinsser Analytic GmbH, Frankfurt, Germany). All
peptides were analyzed by HPLC and found to be 
 
.
 
90% pure.
They were dissolved in RPMI and stored at 
 
2
 
20
 
8
 
C in aliquots.
 
Proliferation Assays of Fresh PBMCs.
 
PBMCs were separated
from whole blood by centrifugation on a density gradient (Lym-
phoprep; Nycomed Amersham plc, Little Chalfont, Bucks, UK) and
were washed and cultured in RPMI 1640 containing glutamine,
penicillin/streptomycin, and 10% heat-inactivated human A–pos-
itive serum. PBMCs were cultured with or without antigens in
medium at 2 
 
3 
 
10
 
5
 
 cells/well in round-bottomed 96-well plates
in a total volume of 200 
 
m
 
l. Triplicate wells were set up for each
antigen, which included PHA and tetanus toxoid (2 
 
m
 
g/ml), and
the pooled peptides covering all of p24 or p17 at 1 and 0.2 
 
m
 
M
concentrations. After 72 h, cultures were pulsed with 1 
 
m
 
Ci of
[
 
3
 
H]thymidine per well for 16 h before harvesting and counting
in a flat-bed scintillation counter (Wallac, Turku, Finland). Re-
sults are expressed either as cpm or stimulation indices (SI 
 
5
 
 cpm
in the presence of antigen/cpm without antigen). An SI 
 
.
 
2.5
was regarded as positive. As variant peptides were identified by
sequencing, some of these were tested in fresh proliferation assays.
 
Isolation of T Cell Lines.
 
PBMCs were separated from whole
blood, and the CD8
 
1
 
 lymphocytes were removed using Dyna-
beads (Dynal A.S., Oslo, Norway). The CD8-depleted cells were
then grown in culture medium at 4 
 
3 
 
10
 
6
 
 in 1 ml for 6 d in the
presence of 10 
 
m
 
g of the relevant pooled peptides. Lymphoblasts
were separated on Percoll on day 7 and then cultured in medium
containing 10% IL-2 (Lymphocult-T; Biotest AG, Frankfurt,
Germany). Lines were expanded using an alternating cycle of re-
stimulation with peptide pool
 
 
 
plus irradiated (30 Gy) autologous
PBMCs as APCs followed by culture in IL-2. The epitopes were
mapped using individual peptides, and the phenotype of the cells
was determined by FACScan
 
Ò
 
 (Becton Dickinson, San Jose, CA)
analysis. Once the individual peptide epitopes had been identi-
fied, the lines were maintained using the relevant peptide at 0.1
 
m
 
g/ml as the antigenic stimulus.
Proliferation assays on the T cell lines were performed as de-
scribed for fresh PBMCs using 5 
 
3 
 
10
 
4
 
 T cells plus 10
 
5
 
 irradiated
(30 Gy) autologous PBMCs as APCs in a final 200 
 
m
 
l volume.
 
Identification of Restricting HLA Class II Molecules.
 
To identify
the restricting HLA class II isotype of the T cell lines, antigen
presentation by autologous APCs was assayed after addition of
mAb against HLA-DR (L243), -DQ (Genox 3.53), or -DP
(B7.21) at the beginning of the culture time. To identify the re-
stricting allele, HLA-sharing or mismatched PBMCs from healthy
donors were used as APCs. Mouse cells (L cells) transfected with
HLA-DRB52c (obtained from Istituto Nazionale per la Ricerca
sul Cancro, Genoa, Italy) were used as APCs to identify T cells
restricted by this allele using uninfected L cells as control. In brief,
5 
 
3 
 
10
 
4
 
 T cells were cocultured with mouse L cells (5 
 
3 
 
10
 
4
 
/
well) plus 1 
 
m
 
M of the relevant peptide.
 
HLA Typing.
 
HLA typing was carried out using sequence-
specific primer PCR as described previously (13).
 
Detection of Secreted IL-2.
 
Identical cultures were set up in a
separate 96-well plate for proliferation assays and for detection of
secreted IL-2. Additionally, 20 
 
m
 
l of anti–IL-2R antibody was
added to each well to prevent the use of secreted IL-2 by the
cells. 100 
 
m
 
l of supernatant was collected from the T cell cultures
after 7 d and frozen at 
 
2
 
20
 
8
 
C until ready to assay. The IL-2–
dependent cell line CTLL was used to assay for IL-2 production.
8 
 
3 
 
10
 
3
 
 CTLL cells per well were grown in RPMI plus 20% FCS
in the presence of doubling dilutions of cell culture supernatants
or in known concentrations of IL-2 standard. After 24 h of cul-
ture, the plate was labeled with [
 
3
 
H]thymidine for 16 h and then
harvested. The amount of IL-2 produced was assessed according
to the standard curve obtained using known amounts of IL-2.
 
Antagonism Assay.
 
Antagonism assays were carried out ac-
cording to the method of De Magistris et al. (14). APCs (autolo-
gous or HLA class II–matched PBLs) were pulsed with a subopti-
mal dose of the relevant index peptide for 2 h at 37
 
8
 
C and then
washed twice. They were then pulsed for an additional 2 h with
varying concentrations of potential antagonist peptides, washed,
and irradiated. 10
 
5
 
 of these APCs were added to wells containing
2.5 
 
3 
 
10
 
4
 
 T cells along with the relevant controls and cultured
for 72 h before labeling with [
 
3
 
H]thymidine and harvesting.
 
Sequencing of Proviral DNA.
 
DNA was purified from patients’
PBMCs after 24–48 h of culture with PHA and extracted using
proteinase K. PCR primers were as follows: for p24-1, external
5
 
9
 
 primer 5
 
9
 
-GTAAGAAAAAAGCACAGCAAGC-3
 
9
 
, external
3
 
9
 
 primer 5
 
9
 
-TTTCTCCTACTGGGATAGGTGG-3
 
9
 
, internal 5
 
9
 
primer 5
 
9
 
-GCTAGAATTCCCAGCAAGCAGCAGCTGACA-3
 
9
 
,
and internal 3
 
9
 
 primer 5
 
9
 
-CTAGATCTAGATGGATTATTT-
GTCATCCATCC-3
 
9
 
; for p17-3, external 5
 
9
 
 primer 5
 
9
 
-ACTAG-
CGGAGGCTAG-3
 
9
 
, external 3
 
9
 
 primer 5
 
9
 
-GTTCTAGGTGATA-
TGG-3
 
9
 
, internal 5
 
9
 
 primer 5
 
9
 
-GCTAGAATTCCATGGGT-
GCGAGAGCGT-3
 
9
 
, and internal 3
 
9
 
 primer 5
 
9
 
-CAGTTCTA-
GATCTAGTATAATTTTGGCTGACC-3
 
9
 
. At any one time
point, at least 20 M13-HIV clones were sequenced to identify the
viral variants present (8).
 
Peptide Binding Studies.
 
These were carried out according to
the method of Davenport et al. (15) using a competitive binding
assay. This determines the ability of a peptide to compete with bio-
tinylated invariant chain (Ii) for binding to affinity-purified MHC
class II molecules. The amount of biotinylated Ii bound was quanti-
tated using an avidin–horseradish peroxidase conjugate system. The
results were expressed as IC
 
50
 
, the concentration of peptide neces-
sary to reduce the binding of Ii to 50% of the noninhibited value.
 
Results
 
Screening
 
43 HIV-1 seropositive patients were screened for prolif-
erative responses to the mitogen PHA, the recall antigen
tetanus toxoid, and HIV-1 antigens consisting of pooled
peptides covering Gag p24 and p17 (Table 1). 19 individu-
als (44%) showed a response to PHA only, 12 (28%) a re-
sponse to PHA and tetanus toxoid only, and the remaining
12 (28%) a response to PHA, tetanus toxoid, and one or
 
1
 
Abbreviations used in this paper:
 
 aa, amino acid(s); Ii, invariant chain; SI,
stimulation index. 
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both of the HIV-1 antigens. All cultures in which a prolif-
erative response to HIV-1 peptides was detected also
showed an increase in IL-2 production. T cell lines from
two patients, 744 and 024, were then used to map and
characterize the natural epitopes that evoked these HIV-1
proliferative responses.
When the epitopes had been mapped and their natural
variants identified, proliferation assays were performed on
fresh PBMCs from the two patients to assess the capacity of
HLA-bound altered peptides to stimulate the prevailing T
cell specificities.
 
Patient 744
 
Epitope Mapping.
 
Patient 744 is a male Caucasian ho-
mosexual who acquired HIV-1 in 1993. His initial CD4
count was 580 cells/
 
m
 
l on day 0 of the study and had de-
clined to 280 by day 323. His HLA type is A24/74; B35/
44; DR1/12, DR52. A proliferation assay performed on
fresh PBMCs from this patient showed a response to PHA,
tetanus toxoid, and pooled p24 peptides but not to p17. An
8-wk-old T cell line showed that a single dominant
epitope, p24-1, representing aa 1–20 of p24 Gag (PIVQN-
LQGQMVHQAISPRTL) was recognized (Fig. 1 
 
A
 
).
FACScan
 
Ò
 
 analysis revealed this line to be 97% CD4
 
1
 
, 0%
CD8
 
1
 
. After antigen stimulation, the T cell line produced
IL-2, consistent with a Th1 phenotype (data not shown).
HLA-matched and mismatched PBMCs used as APCs, and
blocking studies using mAbs to HLA-DR, -DQ, and -DP,
revealed the HLA class II–restricting molecule to be HLA-
DR1 (Fig. 1 
 
B
 
). p24-1 was the sole antigen recognized re-
peatedly from Gag in four assays performed on blood sam-
ples taken over a 1- and an 18-mo period. Assays of fresh
PBMCs confirmed the response to p24-1 (Table 2).
 
Epitope Variation.
 
Nine variants of the p24-1 epitope in
744 HIV-1 proviral DNA were detected and synthesized
(Fig. 2). Other shorter (11-mer) peptides were also made to
determine the requirement for binding to HLA-DR1. These
peptides were also tested for their affinity for HLA-DR1.
 
Peptide Binding.
 
Peptide binding is shown in Table 3.
Truncated peptide studies revealed that loss of the NH
 
2-
terminal aa PIVQ (p24-1/13) abolished binding. Loss of
Table 1. Summary of Patient Clinical Data and Proliferative Responses
Proliferative responses to: PHA only
PHA and tetanus
toxoid only
PHA, tetanus toxoid,
and HIV antigens Total
No. of patients 19 (44%) 12 (28%) 12 (28%) 43
Mean CD4 counts (cells/ml) 351 6 169 350 6 153 497 6 148 398 6 167
Length of time of infection (yr) ,1–10 ,1–8 ,1–4 ,1–10
Mean proliferation (SI) to:
PHA 49 6 53 78 6 118 138 6 170 82 6 118
Tetanus toxoid ,1 45 6 117 31 6 32 21 6 65
HIV antigens ,1 ,1 15 6 18 5 6 11
Results are expressed as SI 5 mean cpm of PBMCs plus antigen/mean cpm of PBMCs alone. HIV antigens, pools of overlapping peptides covering
all of Gag p24 or Gag p17.
Figure 1. (A) Identification of
HIV p24 Gag epitope recognized
by T cell line 744. Proliferation
assays were performed by cultur-
ing 5 3 104 T cells with 105 irra-
diated (30 Gy) autologous PB-
MCs as APCs with or without 1
mM peptide for 3 d. Peptides
used to verify the specificity of
the Gag response were as follows:
p24-1, aa 133–153, PIVQNL-
QGQMVHQAISPRTL; p24-2,
aa 143–163, VHQAISPRTL-
MAWVKVVEEK; p24-3, aa
153–173, MAWVKVVEEKAF-
SPEVIPMF; and p24-4, aa 163–183, AFSPEVIPMFSALSEGATQP. Cells were labeled with 1 mCi [3H]thymidine per well for 16 h, harvested, and
counted on a beta counter. APC only, cpm obtained for T cells and APCs only. (B) Identification of the MHC haplotype that restricts presentation of an-
tigen to T cell line 744. HLA class II–restricting elements were determined by proliferation assays using HLA-matched and mismatched PBMCs from
healthy donors as APCs in the presence or absence of 1 mM peptide p24-1. HLA type of patient 744 (autol.APC) was A24/74;B35/44;DR1/12, DR52.
Donor DR1/2 was homozygous for DR1.1788 HIV-1 Variation within CD4 Epitopes
the COOH-terminal aa sequence AISPRTL (P24-1/11) did
not interfere with binding. These results imply that the core
sequence VQNLQGQMV (p24-1/12) is sufficient to mimic
binding (but not necessarily antigenicity) of the natural
epitope. Subsequent studies showed the importance of the
NH2-terminal aa PI for TCR recognition of this epitope.
Two other peptide sequences, p24-1/18 (HIV-1 con-
sensus H) and 20 (HIV-1; our unpublished results), bound
well to HLA-DR1. Of the nine natural variants from pa-
tient 744, all bound well. Although variant p24-1/19
bound less well to HLA-DR1, this peptide stimulated T
cells, so this difference was not functionally significant in
this assay system.
CD4 T Lymphocyte Responses to p24-1 Peptide Variants.
Of five truncated peptides tested, only p24-1/11 stimulated
a line from patient 744 (Fig. 3). Since both p24-1/11 and
12 bound well in the assay, this result implies that NH2-ter-
minal proline and isoleucine were required for T cell rec-
ognition. The peptides p24-1/13, 14, and 15 failed to bind
and failed to stimulate the T cell line.
Natural Variants. In assays of fresh PBMCs, the most
common variant, p24-1/16, failed to stimulate proliferation
(Table 2), although this sequence bound well (Table 3),
whereas the index peptide p24-1 elicited a significant re-
sponse. This result was confirmed when p24-1/16 and
other variants were tested against a T cell line from this pa-
tient. Three peptides, p24-1/21, 23, and 25, elicited an SI
,1 and yet had satisfactory binding (Table 3). Thus, loss of
recognition was likely to be caused by loss of TCR engage-
ment or signaling, rather than failure of presentation.
To investigate whether these variant peptides could an-
tagonize the CD4 helper response to virus, we identified
two peptides (p24-1/16 and p24-1/25; see Table 3) in
which there was no T cell recognition but in which the aa
changes were conservative as potential antagonists (14). The
p24-1/16 viral variant comprised 100% of the virus in this
patient on day 0 and was a common variant subsequently
(Fig. 2). Despite several attempts to demonstrate an antago-
nist effect with peptides (p24-1/16 and p24-1/25) on the
response to wild-type p24-1, no inhibition was seen.
Patient 024
Epitope Mapping. Patient 024 is a male Caucasian HIV-
11 homosexual. His CD4 count was 780 on day 1 of the
study and 800 on day 335. His HLA type is A3/30; B13/
37; DR15/13.02; DR51/52; DQ6. PBMCs from this pa-
tient showed a strong proliferative response to p17 pooled
Table 2. Proliferative Responses of Fresh PBMCs from Patients 
744 and 024 over Time
Patient 744
Day of bleeding Day 0 Day 56 Day 178 Day 498
PHA 44 12 385 nt
Tetanus toxoid 40 nt 6 nt
Gag p24 peptide pool 10 3.3 3.2 19
p24-1 nt 3.2 5.6 11
p24-1/16 variant nt nt nt 1.1
Patient 024
Day of bleeding Day 0 Day 29 Day 271
PHA 239 126 400
Tetanus toxoid 98 nt
Gag p17 peptide pool 63 25 18
p17-3 24 21 25
p17-3/1 nt nt 1
p17-3/2 nt nt 1.1
p17-3/3 nt nt 3.7
p17-3/4 nt nt 1.3
Results are expressed as SI 5 mean cpm of PBMCs 1 antigen/mean
cpm of PBMCs alone. SI .2.5 was regarded as a positive response. nt,
not tested.
Figure 2. Naturally occurring
variants of p24-1 Gag from pa-
tient 744. Proviral DNA was pu-
rified from PBMCs of patient
744 collected at intervals. The
region of interest was amplified
by nested PCR and sequenced.
At least 20 clones were studied
to identify any variants.1789 Harcourt et al.
peptides and to peptide p17-3, aa 21–35 of p17 (LRPG-
GKKKYKLHIV; data not shown). This peptide sequence
contains a known cytotoxic T cell epitope, usually re-
stricted by HLA-A3 (16) or -B8 (8). Since this patient is
HLA-A31, we ensured that only CD4 lymphocyte prolif-
eration was measured by depleting CD81 lymphocytes be-
fore assay or culture. Proliferation assays performed using
total PBMCs, CD8-depleted lymphocytes, and CD81 lym-
phocytes revealed that the response measured was confined
to the CD8-depleted population (data not shown). T cell
lines grown out from fresh PBMCs were shown to be
CD41 by FACScanÒ analysis. This cell line had a Th1 phe-
notype, since IL-2 was produced on stimulation with anti-
gen. Using HLA-matched and mismatched PBMCs as APCs,
the HLA restriction molecule was initially identified as
DR13.02. Peptide binding studies using purified DR13.02
showed that p17-3 binds very poorly if at all to this allele
(IC50 . 100 mM). Since DR52c is invariably associated
with DR13.02, we used mouse L cells transfected with
HLA-DR52c to present peptide p17-3 and confirmed that
this was the restricting allele. Although presentation of
p17-3 by the L cells was not optimal, probably because of a
lack of accessory molecules, there was a fivefold increase in
cpm over that obtained with the control untransfected L
cells, confirming that DR52c was the class II restricting
molecule for p17-3.
Sequencing of proviral DNA from this patient over 12 mo
showed considerable variation (Fig. 4). There are four
commonly identified naturally occurring variants of HIV-1
SF2 p17-3 in the database:
Table 3. The Binding Affinity (IC50) of p24-1 Variant Peptides to HLA-DR1
Peptide no. Peptide
Binding results
IC50 av.* IC50/index‡
Truncated peptides
p24-1/11 PIVQNLQGQMV 0.07 1.75
p24-1/12 VQNLQGQMVHQ 0.08 2
p24-1/13 NLQGQMVHQAI 8.74 475
p24-1/14 QGQMVHQAISP 11.77 600
p24-1/15 QMVHQAISPRTL 6.62 325
p24-1/26 VQNLQGQMV 12.79 450
p24-1/27 PGVQNLQGQMVHQ 0.09 2.25
p24-1/28 PIGQNLQGQMVHQ 0.64 16
Ii LPKPPKPVSKMRMATPLLMQ 0.04 1
HA PKYVKQNTLKLAT (306–318) 0.14 3.5
Natural database variants§
p24-1/18 PIVQNAQGQMVHQAISPRTL 0.04 1
p24-1/20 PIVQNLRGQMVHQAISPRTL 0.91 22.75
Natural 744 variants
p24-1 PIVQNLQGQMVHQAISPRTL 0.04 1
p24-1/16 PIVQNIQGQMVHQAISPRTL 0.1 2.5
p24-1/17 PIVQNQQGQMVHQPISPRTL 0.1 2.5
p24-1/19 PIVQNLQGQMVHQPISPRTL 1.19 29.75
p24-1/21 PIAQNIQGQMVHQAISPRTL 0.16 4
p24-1/23 PMVQNIRGQMVHQAISPRTL 0.01 0.25
p24-1/24 PIVQNIQGQVVHQAISPRTL 0.05 1.25
p24-1/25 PIVENIQGQMVHQAISPRTL 0.02 0.5
p24-1/29 FIVQNAQGQMVHQAISPRTL 0.32 8
p24-1/30 PIVENIQGQIIHQAISPRTL 0.44 11
IC50, concentration of peptide required to bind 50% of Ii. Ii, invariant chain CLIP peptide. HA, influenza hemagglutinin peptide.
*Average of triplicate binding assays.
‡IC50 of variant peptides divided by value for index p24-1.
§Reference 28.1790 HIV-1 Variation within CD4 Epitopes
p17-3  aa 20–35 of p17 Gag  LRPGGKKKYKLKHIV
p17-3/1 HIV-1 RF LRPRGKKRYKLKHIV
p17-3/2 HIV-1 CD41 LRPGGKKQYRLKHIV
p17-3/3 HIV-1 MAN LRPGGKKKYQLKHIV
p17-3/4 HIV-1 NDK LRPGGKKKYALKHLI
Two of these, index p17-3 and p17-3/3, occurred in this
individual. p17-3/3, which was the most common variant
detected in patient 024 on days 0 and 335, was recognized
well by the T cell line derived from PBMCs initiated on
day 71, and substantially better than peptide p17-3, which
had been used to grow out the line. The natural database
variants p17-3/1 and p17-3/2 failed to stimulate this line,
whereas p17-3/4 was a strong proliferative agonist (Fig. 5).
The proliferative response of fresh PBMCs on day 271 re-
vealed a marked difference in the capacity of p17-3 epitope
variants to elicit proliferation (Table 2). The index se-
quence, p17-3, which may have been the predominant an-
tigen at that time (Fig. 4), produced a clear positive re-
sponse. The common variant p17-3/3 induced a much
weaker response. This result and the fresh responses to
variants in patient 744 imply that circulating HLA class II–
restricted T lymphocytes do not bear specificities for every
variant antigen present in the infecting virus population.
Discussion
When systematically sought, HIV-1–specific prolifera-
tive responses were present in 28% of our asymptomatic
patients. We mapped the HIV-1–specific Th response in
two individuals to epitopes within HIV-1 Gag. We defined
the HLA class II restriction molecules and determined the
antigenic variation within these epitopes. This work has re-
vealed that natural antigenic variation in an HLA-DR1–
restricted epitope does not lead to loss of HLA class II
binding, but some variants detected failed to stimulate T
cell proliferative responses in fresh uncultured cells and in a
T cell line. Similar results were also demonstrated in an
HLA-DRB52c–restricted p17 Gag epitope variant. These
findings imply that CD4 T lymphocyte help may be di-
minished when these cells fail to be stimulated by natu-
rally occurring HIV-1 antigenic variation.
There is evidence that HIV variants can escape from
CD81 CTL responses (5–10, 17). This escape can arise
through impairment of epitope binding to the presenting
HLA class I molecule (10, 17) or by alterations in residues
in contact with the TCR (5). Can CD41 T cell responses
provide analogous pressure for the generation of escape
mutants? Siliciano et al. (12) demonstrated that HIV ge-
nomic heterogeneity had a profound effect on recognition
by a gp120-specific CD41 line derived from uninfected
donors, suggesting that natural escape in seropositive peo-
ple might occur. In that study, variant peptides induced
three different types of proliferative response. One peptide
Figure 3. Proliferation of T cell line 744 to variant peptides of p24-1
Gag. Recognition of 16 variant peptides (see Table 3) of p24-1 Gag by T
cell line 744 was assayed by proliferation, as described for Fig. 1 A. APC
only, background for T cells and APCs alone, i.e., SI 5 1.
Figure 4. Naturally occurring variants of
p17-3 Gag in patient 024. Viral DNA was
purified from PBMCs of patient 024 at the
time intervals stated. The region of p17-3
was amplified by PCR, cloned, and se-
quenced. At least 20 clones were sequenced
to identify any variants.1791 Harcourt et al.
induced greater proliferation, but the majority showed a
significant reduction in stimulation or no stimulation at all.
Here we show that single aa changes within HLA class II–
restricted epitopes can alter recognition by CD41 T cells as
gauged by diminished proliferative responses. These mu-
tant epitopes could confer a survival advantage on viruses
in an environment where the loss of T cell help impaired
HIV-specific CTL activity against infected cells.
In patients 744 and 024, fresh PBMCs responded to the
mapped peptides (Table 2), confirming the presence of cells
with these specificities in circulating T lymphocytes. In pa-
tient 744, the viral variant p24-1/16 dominated in vivo
(Fig. 2; 100% on day 0, 55% on day 182) and it bound ade-
quately to HLA-DR1. However, it was not recognized by
fresh PBMCs from this patient tested on day 498. Although
results obtained with T cell lines suggest important differ-
ences in the capacity of these cells to recognize variants, the
failure of recognition by fresh uncultured cells is likely to
more closely reflect events in vivo.
Since CD41 lymphocytes failed to proliferate despite ad-
equate binding of the altered peptides to the restricting
HLA-DR1 molecule, the mutation must have impaired
TCR recognition in some way. HLA-DR1 was the first
HLA class II allele to be crystallized (18, 19), and there ap-
pear to be five pockets in the peptide binding groove.
Studies using mutant HLA-DR1 molecules have revealed
that changes in the contact residues of pockets 1, 4, and 7
can greatly alter binding. Hammer et al. (20) proposed a
motif for peptides binding to HLA-DR1 using a phage dis-
play library. This identifies two potential anchor positions,
at positions 1 and 4, and an enrichment for the small aa res-
idues at 6. Peptide p24-1 and its variants all bound well to
HLA-DR1, with affinities comparable to the influenza he-
magglutinin peptide. Our results confirm that HLA-DR1
will tolerate peptide variation since binding in one pocket
can be compensated for elsewhere, stabilizing the interac-
tion. Analysis of the crystal structure of HLA-DR1 com-
plexed with influenza hemagglutinin revealed that z35%
of the peptide remains solvent accessible in the peptide–
MHC complex. Thus, if p24-1 binds in a similar manner to
HLA-DR1, the alteration of any of its exposed peptide res-
idues would directly alter the surface of the peptide–MHC
complex that interacts with the TCR.
Evavold and Allen (21) have described a Th cell specific
for hemoglobin in which the alteration of a single aa in the
immunogenic peptide induced only cytokine secretion and
not proliferation. This shows that the TCR response to
ligand is not an all-or-nothing phenomena and that “partial
signaling” can be triggered by an altered peptide ligand such
as those described here. Purbhoo et al. (11) showed that al-
tered HIV-1 peptide ligands failed to induce phosphoryla-
tion of pp36 in CTLs. Madrenas et al. (22) and Sloan-
Lancaster et al. (23) have also shown that altered peptide
ligands can induce partial signaling in CD41 lymphocytes.
CD41 T cells play a central role in virtually all immune
responses by releasing cytokines that enhance the activity of
immune effector cells such as CD81 T and B cells (24). Os-
sendorp et al. (25) have shown that it is possible to confer
protective immunity to virus-induced tumors by vaccina-
tion with a specific viral Th epitope. The CD41 cells in-
duced acted synergistically with CD81 cytotoxic T cells to
eradicate the tumor. The use of Th epitopes in vaccines
can greatly enhance their efficiency in inducing CTL re-
sponses and maintaining CTL memory, as has been shown
for lymphocytic choriomeningitis virus (26). Lack of Th
responses through engagement with weak agonist peptides
could impair CTL activity in HIV-1 infection (27).
The vast capacity for mutation of HIV-1 has often been
alleged to be a basis for immune escape and viral persis-
tence in this infection. Experimental evidence for this con-
tention has been accumulating in studies of HIV-1–specific
CTL-mediated immunity.
There has been much more uncertainty as to why CD41
lymphocyte responses are impaired. In this study we de-
fined the HIV-1–specific CD4 lymphocyte response by
mapping the peptide epitope and determining the HLA
class II restriction in infected individuals. We also se-
quenced viral variants present in the same patients. This en-
abled us to determine the effect on immune recognition of
natural viral variation. Most peptide variants were capable
of binding to class II and hence could be presented at the
cell surface, but they often failed to stimulate T cell prolif-
eration in both fresh preparations and cell lines. These find-
ings raise important questions regarding the integrity of T
lymphocyte help even during the early phases of HIV-1 in-
fection. It is plausible that within lymph nodes or at other
sites there are T lymphocytes with specficities capable of
recognizing a greater range of variant antigens than are
found circulating in the blood. However, some of the
altered peptides we have identified are likely to be weak
agonists, incapable of driving out proliferative responses.
Dominant variants such as p24-1/16, which always failed
to elicit proliferation in fresh cells and cell lines, could di-
minish the provision of necessary cytokine-mediated help
in vivo. Modern antiretroviral therapy that restored CD4
lymphocyte function might have the additional advantage
of diminishing the prevalence of such variants by switching
off viral replication.
Figure 5. Proliferation of T cell line 024 to variants of p17-3 Gag.
Recognition of peptides by T cell line 024 was assessed by proliferation
assays as described for Fig. 1 A. Sequences of the p17 Gag variant peptides
are as follows: p17-3, LRPGGKKKYKLKHIV; p17-3/1, LRPRGK-
KRYKLKHIV; p17-3/2, LRPGGKKQYRLKHIV; p17-3/3, LRPG-
GKKKYQLKHIV; and p17-3/4, LRPGGKKKYALKHLI.1792 HIV-1 Variation within CD4 Epitopes
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